Low sales, high cost: Melinta slashes HQ research staff as it struggles to grow antibiotics revenue
Look to Melinta Therapeutics for the latest sign of economic trouble in the antibiotics field.
Exactly a year after the Connecticut drugmaker executed a $270 million pact to buy out The Medicines Co’s infectious disease group — one in a string of pipeline expansion deals — the company is reportedly closing down its headquarters and laying off 22 out of 25 staff and spinning out research projects, the local New Haven Biz reported last week. The bulk of the cuts were in R&D.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.